Analys

Lytix Biopharma (Q3 Review): Positive Clinical Readouts - Redeye

{newsItem.title}

Redeye Publicerad: 18 Nov 15:41

Lytix Biopharma

Redeye comments on Lytix' third quarter report 2025. After the quarter, positive results were presented in both main programmes. Lytix presented a strong interim readout in NeoLIPA, the study in neoadjuvant melanoma, while Verrica disclosed immune activation in biopsies of BCC.

Länk till analysen i sin helhet: https://www.redeye.se/research/1138328/lytix-biopharma-q3-review-positive-clinical-readouts?utm_source=finwire&utm_medium=RSS

Nyheter om Lytix Biopharma

Läses av andra just nu

Om aktien Lytix Biopharma

Senaste nytt